About: http://data.cimple.eu/news-article/c3fb5c833dc1f112fbc81f38ea4df4485c10a8cbcc155050afc8b7cb

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: http://data.cimple.eu/news-article/c3fb5c833dc1f112fbc81f38ea4df4485c10a8cbcc155050afc8b7cb Goto Sponge Distinct Permalink

An Entity of Type : schema:NewsArticle, within Data Space : data.cimple.eu associated with source document(s)

Attributes	Values
rdf:type	schema:NewsArticle
schema:articleBody	Pharma giant AstraZeneca said Tuesday it had begun a clinical trial of a drug designed to both prevent infection and treat people with COVID-19, with the first volunteers receiving doses. The drug, known as AZD7442, is a combination of two antibodies and is being tested on 48 healthy people aged between 18 and 55, the company said. "This trial is an important milestone in the development of our monoclonal antibody combination to prevent or treat COVID-19," said Mene Pangalos, executive vice-president of biopharmaceuticals research and development at AstraZeneca. The company said the trial would help evaluate the safety of the drug and be used both to prevent the disease and to stop it from progressing in patients already infected. Results from the trial are expected by the end of this year. This latest trial involving AstraZeneca, which has its global headquarters in Cambridge, eastern England, comes in addition to its partnership with the University of Oxford on the development of a separate coronavirus vaccine, which is said to have produced encouraging results. News of the latest trial prompted shares in AstraZeneca to rise in early trading on Tuesday. dmh/phz/bmm
schema:headline	AstraZeneca starts UK covid-19 drug trial
schema:mentions	Cambridge Clinical trial Hertz University of Oxford AstraZeneca United Kingdom Vaccine Severe acute respiratory syndrome coronavirus 2 Coronavirus disease 2019 Theodoros Pangalos (general) Monoclonal antibody Biopharmaceutical
schema:author	http://data.cimple.eu/organization/1f0054d541e000623a2c1e561a247c073ef6328e8be9ffafda7b3fcd
schema:datePublished	2020-08-25 (xsd:date)
http://data.cimple...sPoliticalLeaning	other political leaning
http://data.cimple...logy#hasSentiment	positive sentiment
http://data.cimple...readability_score	86 (xsd:integer)
http://data.cimple...tology#hasEmotion	happiness

Faceted Search & Find service v1.16.115 as of Oct 09 2023

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3238 as of Jul 16 2024, on Linux (x86_64-pc-linux-musl), Single-Server Edition (126 GB total memory, 11 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software